RPTR-1-201 / Repertoire - LARVOL DELTA

Repertoire Immune Medicines…announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to RPTR-1-201 for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) after progression on, or intolerance to, available standard therapies. (PRNewswire) - "RPTR-1-201 is a novel T cell receptor (TCR) bispecific immune medicine that is currently in a Phase 1/2 trial for the treatment of multiple advanced solid tumors."

Fast track • Triple Negative Breast Cancer

RPTR-1-201-101: An early phase trial of RPTR-1-201 in Advanced Solid Tumors (clinicaltrialsregister.eu) - P1/2 | N=52 | Not yet recruiting | Sponsor: Repertoire Immune Medicines Inc.

New P1/2 trial • Oncology • Solid Tumor

RaPTR-101: An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=150 | Recruiting | Sponsor: Repertoire Immune Medicines | Not yet recruiting ➔ Recruiting

Enrollment open • Solid Tumor

RaPTR-101: An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=150 | Not yet recruiting | Sponsor: Repertoire Immune Medicines

New P1/2 trial • Solid Tumor